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Introduction
Mesenchymal Stem Cells (MSC) are adult stem cells
which are mainly present in bone marrow and fat. The cell
is a fine candidate for treatment of juvenile idiopathic
arthritis since it has strong immunosuppressive activities
in vitro as well as in vivo [1,2].
Methods
We performed a study with 104 Balb/c mice with 55 as
donors of MSC. The 49 mice that were induced twice with
human proteoglycan for the development of PGIA were
randomly assigned to 5 groups: 1 control-group (PBS)
and 4 treatment-groups (MSC once or twice intraperito-
neal [ip] or intra-articular [ia]). Ten days after 2nd PG-anti-
gen injection, treatment was started and if planned again
after 4 weeks. Dosages were 5 × 106 ip and 1 × 106 cells ia.
MSC used were syngeneic and passaged twice. Arthritis
was scored 2 times a week by 2 independent observers
according to a scoringsystem with a maximum of 16.
Results
Arthritis-score was on average 1.3 (0.8–2.0) just before
start of the treatment and increased to 6.0 in the control
group towards the end of the experiment (day 67). At day
67 arthritis-scores were significantly lower in both ip-
groups (1.0 and 0.5) and in the repeated ia-group (2.0).
Furthermore in both ip-groups arthritis-scores decreased
after treatment and stabilized until day 67.
Conclusion
High dose MSC systemically administered (ip) has good
clinical effect on established arthritis. Arthritisscore not
only stabilized but even diminished after injection of ip
MSC. Ip injection of MSC once was as good as twice; this
was not true for the ia injection.
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